Skip to main content

Research Repository

Advanced Search

All Outputs (6)

Lifespan pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI (2018)
Journal Article
Xing, Y., Sapuan, A., Dineen, R., & Auer, D. P. (2018). Lifespan pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI. Movement Disorders, 33(11), 1792-1799. https://doi.org/10.1002/mds.27502

Background: Neuromelanin is a pigment with strong iron-chelating properties preferentially found in dopaminergic neurons of the substantia nigra, pars compacta (SNpc). Parkinson's disease is characterized by pronounced, MRI detectable neuromelanin lo... Read More about Lifespan pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI.

How do spatially distinct frequency specific MEG networks emerge from one underlying structural connectome? The role of the structural eigenmodes (2018)
Journal Article
Tewarie, P., Abeysuriya, R., Byrne, Á., O'Neill, G. C., Sotiropoulos, S. N., Brookes, M. J., & Coombes, S. (2019). How do spatially distinct frequency specific MEG networks emerge from one underlying structural connectome? The role of the structural eigenmodes. NeuroImage, 186, 211-220. https://doi.org/10.1016/j.neuroimage.2018.10.079

Functional networks obtained from magnetoencephalography (MEG) from different frequency bands show distinct spatial patterns. It remains to be elucidated how distinct spatial patterns in MEG networks emerge given a single underlying structural networ... Read More about How do spatially distinct frequency specific MEG networks emerge from one underlying structural connectome? The role of the structural eigenmodes.

Hypoxia imaging with [18F]HX4 PET in squamous cell head and neck cancer: a pilot study for integration into treatment planning (2018)
Journal Article
Betts, H. M., O'Connor, R. A., Christian, J. A., Vinayakamoorthy, V., Foweraker, K., Pascoe, A. C., & Perkins, A. C. (2019). Hypoxia imaging with [18F]HX4 PET in squamous cell head and neck cancer: a pilot study for integration into treatment planning. Nuclear Medicine Communications, 40(1), 73-78. https://doi.org/10.1097/MNM.0000000000000933

Background: Radical chemoradiotherapy is the primary treatment for head and neck cancers in many hospitals. Tumour hypoxia causes radiotherapy resistance, and is an indicator of poor prognosis for patients. Identifying hypoxia to select patients for... Read More about Hypoxia imaging with [18F]HX4 PET in squamous cell head and neck cancer: a pilot study for integration into treatment planning.

Automated quality control for within and between studies diffusion MRI data using a non-parametric framework for movement and distortion correction (2018)
Journal Article
Bastiani, M., Cottaar, M., Fitzgibbon, S. P., Suri, S., Alfaro-Almagro, F., Sotiropoulos, S. N., …Andersson, J. (2019). Automated quality control for within and between studies diffusion MRI data using a non-parametric framework for movement and distortion correction. NeuroImage, 184, 801-812. https://doi.org/10.1016/j.neuroimage.2018.09.073

Diffusion MRI data can be affected by hardware and subject-related artefacts that can adversely affect downstream analyses. Therefore, automated quality control (QC) is of great importance, especially in large population studies where visual QC is no... Read More about Automated quality control for within and between studies diffusion MRI data using a non-parametric framework for movement and distortion correction.

Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma (2018)
Journal Article
Grill, J., Massimino, M., Bouffet, E., Azizi, A. A., McCowage, G., Cañete, A., …Giangaspero, F. (2018). Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma. Journal of Clinical Oncology, 36(10), https://doi.org/10.1200/JCO.2017.76.0611

Purpose Bevacizumab (BEV) is approved in more than 60 countries for use in adults with recurrent glioblastoma. We evaluated the addition of BEV to radiotherapy plus temozolomide (RT+TMZ) in pediatric patients with newly diagnosed high-grade glioma (... Read More about Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma.